ClinicalTrials.gg

TargetBeta

ACHE

acetylcholinesterase (Yt blood group) · also YT · Blood group antigens

4 programs in company-led studies act on ACHE, from 4 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
huperzine AruleWanbangde Pharmaceutical Groupphase 472 running–ChEMBL
DonepezilruleEisaiphase 4831 running–ChEMBL
benzgalantamine gluconateruleAlpha Cognitionphase 411 running–ChEMBL
Z 338ruleZeria Pharmaceuticalphase 3121 running–ChEMBL

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.